Atea Pharmaceuticals, Inc.

NasdaqGS:AVIR Stock Report

Market Cap: US$277.7m

Atea Pharmaceuticals Future Growth

Future criteria checks 2/6

Atea Pharmaceuticals's earnings are forecast to decline at 4.8% per annum while its annual revenue is expected to grow at 119.2% per year. EPS is expected to grow by 13.1% per annum. Return on equity is forecast to be -65.4% in 3 years.

Key information

-4.8%

Earnings growth rate

13.1%

EPS growth rate

Pharmaceuticals earnings growth23.6%
Revenue growth rate119.2%
Future return on equity-65.4%
Analyst coverage

Low

Last updated16 Sep 2024

Recent future growth updates

Recent updates

Atea wins FDA Fast Track status for dengue treatment

Sep 26

Atea Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story

May 13
Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story

Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically

Jan 05
Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates

Nov 25
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Oct 24
A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Oct 24
A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)

Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir

Oct 20

U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs

Jun 17

Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

May 15
Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

May 13
Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%

Apr 08
Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%

Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business

Mar 06
Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business

Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares

Jan 30
Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares

Earnings and Revenue Growth Forecasts

NasdaqGS:AVIR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202632-211-192-1662
12/31/20258-181-204-1783
12/31/2024N/A-192-108-812
6/30/2024N/A-176-121-121N/A
3/31/2024N/A-164-95-95N/A
12/31/2023N/A-136-85-85N/A
9/30/2023N/A-131-85-85N/A
6/30/2023N/A-106-89-89N/A
3/31/2023N/A-109-94-92N/A
12/31/2022N/A-116-123-121N/A
9/30/202219236-177-175N/A
6/30/202222516-133-131N/A
3/31/202228548-129-129N/A
12/31/2021351121-87-87N/A
9/30/202120825307307N/A
6/30/202117535275275N/A
3/31/202111524284284N/A
12/31/202049-11297297N/A
9/30/2020N/A-36-26-26N/A
6/30/2020N/A-22-20-20N/A
3/31/2020N/A-16-14-14N/A
12/31/2019N/A-14-13-13N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AVIR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AVIR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AVIR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AVIR's revenue (119.2% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: AVIR's revenue (119.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AVIR is forecast to be unprofitable in 3 years.


Discover growth companies